Fallon · Brain, behavior, & immunity - health 2020 · case-control study · n=179

Anti-lysoganglioside and other anti-neuronal autoantibodies in post-treatment Lyme Disease and Erythema Migrans after repeat infection.

Cited 16 times in the scientific literature.

Level 4 - case-series / case-control

Case-control observational study comparing autoantibody levels and cellular signaling across patient groups and controls

PubMed 34589824 · doi:10.1016/j.bbih.2019.100015 · record verified 2026-08-27

What was done

Serum antineuronal IgG titers against lysoganglioside GM1, tubulin, and dopamine receptors (D1R and D2R) were measured via ELISA across 179 participants: 24 with recent Erythema Migrans (EM) without prior Lyme disease (LD), 8 with recent EM and prior LD, 119 with persistent post-treatment LD symptoms (PTLS), and 28 seronegative endemic controls. Serum antibody-mediated signaling of calcium calmodulin-dependent protein kinase II (CaMKII) activity was also measured in a human neuronal cell line (SK-N-SH).

What was found

The EM with prior LD group (n = 8) showed significantly higher titers than controls for anti-lysoganglioside GM1 (p = 0.002), anti-tubulin (p = 0.03), and anti-D1R (p = 0.02), as well as increased antibody-mediated CaMKII signaling (p = 0.03). The PTLS group (n = 119) showed significantly higher anti-lysoganglioside GM1 titers than controls (p = 0.01) but not for the other markers. The primary EM group without prior LD (n = 24) showed no significant differences compared to controls. Absolute titer values were not reported in the abstract.

Why it matters

The findings suggest that repeat Borrelia burgdorferi exposure may induce an immune priming effect that elevates antineuronal antibodies with functional signaling activity, and that anti-lysoganglioside antibodies may play a role in persistent post-treatment symptoms.

Limits

The repeat EM subgroup was very small (n = 8), limiting statistical power. The study is cross-sectional and cannot establish whether autoantibodies cause symptoms or are incidental post-infectious markers. Absolute concentrations and clinical symptom correlations were not reported in the abstract.

Cited by